Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

‘Historic’ results for breast cancer drug and promise for broader use

February 21, 2022 Sales and Marketing

AstraZeneca has shared that its drug, Enhertu, has demonstrated meaningful survival improvements in patients with breast cancer, compared with physician’s …
News

FDA considers approving second COVID-19 booster jab

February 21, 2022 Sales and Marketing

US health regulators are looking at authorising a potential fourth dose of a COVID-19 vaccine, as reported by the Wall …
News

FDA approves Eversense CGM system for use for up to six months

February 14, 2022 Sales and Marketing

The FDA has approved Senseonics’ Eversense E3 CGM System, which includes proprietary sacrificial boronic acid (SBA) technology to extent longevity …
News

AbbVie submits applications for treatment of chronic disease

February 14, 2022 Sales and Marketing

AbbVie has announced the submission of applications seeking the approval of upadacitinib, (RINVOQ®, 15 mg once daily) for the treatment …
News

Gilead’s HIV treatment demonstrates high efficacy and viral suppression at five years

February 14, 2022 Sales and Marketing

Gilead Sciences has announced the presentation of cumulative five-year results from two Phase III studies of Biktarvy. The new, long-term …
News

First UK Lassa fever death in over a decade

February 14, 2022 Sales and Marketing

A patient in Bedfordshire has died from a confirmed case of Lassa fever, the UK Health Security Agency (UKHSA) has …
News
fejiomfxwaeana8

First gene therapy for rare genetic neurodegenerative disorder in children

February 7, 2022 Sales and Marketing

NICE has published a draft highly specialised technologies guidance, recommending gene therapy atidarsagene autotemcel for some children with the rare, …
News

NICE approves new treatment for chronic heart failure

February 7, 2022 Sales and Marketing

Empagliflozin (Jardiance®) has received a positive NICE recommendation for the treatment of chronic heart failure. NICE has announced that empagliflozin …
News

FDA approves Vabysmo to treat vision-threatening retinal conditions

January 31, 2022 Sales and Marketing

The FDA has approved vabysmo (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration and diabetic macular edema. …
News

Almirall announces licensing agreement to accelerate antibody drug discovery

January 31, 2022 Sales and Marketing

Almirall has announced a multi-target licensing agreement with Ablexis, focussed on licensing its AlivaMab Mouse technology, and a research collaboration …
News

Positive CHMP opinion for treatment of rare unpredictable disease

January 31, 2022 Sales and Marketing

Blueprint Medicines has announced that the CHMP has adopted a positive opinion recommending to expand the current indication for AYVAKYT® …
News

CHMP recommends approval of dupixent for children with severe asthma

January 31, 2022 Sales and Marketing

The EMA’s CHMP has adopted a positive opinion recommending the extension of the approval of Dupixent (dupilumab) for children with …
News

Ascletis begins Phase III trial into bevacizumab for treatment of recurrent glioblastoma

January 24, 2022 Sales and Marketing

Ascletis Pharma has announced the dosing of the first patient in the Phase III registration clinical trial of ASC40, combined …
News

Pfizer: Annual COVID shots preferable to frequent boosters

January 24, 2022 Sales and Marketing

Pfizer CEO Albert Bourla has commented that an annual COVID-19 vaccine would be preferable to more frequent booster shots in …
News

NICE expands guidance for lokelma in adult patients with persistent hyperkalaemia

January 24, 2022 Sales and Marketing

NICE have updated the Technology Appraisal Guidance (TAG) for Lokelma (sodium zirconium cyclosilicate SZC) in the treatment of adult patients …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026